Kantoff Philip W. 4

What Happened Philip W. Kantoff, a director of Context Therapeutics, was granted 45,000 derivative shares/options on June 24, 2026. The reported acquisition price is $0.00, indicating this was a grant/award of equity rather than a market purchase or exercise—no cash was exchanged at the time of the grant. The filing classifies the transaction as a derivative award (transaction code A).

Key Details

• Transaction date: 2026-06-24; Form 4 filed: 2026-06-26.
• Security/amount: 45,000 derivative shares/options; reported price per share: $0.00.
• Transaction code: A (award/grant/acquisition of derivative securities).
• Vesting/exercisability: Per footnote, the option vests and becomes exercisable on the earlier of (i) June 24, 2027 (one-year anniversary of grant) or (ii) the issuer’s 2027 annual meeting of stockholders, subject to continued service.
• Shares owned after transaction: Not specified in the provided data.
• Timeliness: Filing occurred two days after the transaction date and was not flagged as late in the provided record.

Context This was a grant of derivative securities (an option award) rather than an immediate purchase or sale of common stock. Such awards are typically subject to vesting and service conditions (here, a one-year/meeting-based vesting), and do not necessarily indicate immediate buying or selling activity. Because the grant price is $0.00, the ultimate value to the insider depends on Context Therapeutics' future share price and any applicable exercise price and terms.